VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
about
VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in miceIsolation and identification of antitrypanosomal and antimycobacterial active steroids from the sponge Haliclona simulansVamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor.VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.Meeting Report: New Directions in the Biology and Disease of Skeletal Muscle 2014Pharmacologically-induced mitotic synchrony in airway epithelial cells as a mechanism of action of anti-inflammatory drugsIL-1β induction of MUC5AC gene expression is mediated by CREB and NF-κB and repressed by dexamethasone.Human interstitial cellular model in therapeutics of heart valve calcification.VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.226th ENMC International Workshop:: Towards validated and qualified biomarkers for therapy development for Duchenne muscular dystrophy 20-22 January 2017, Heemskerk, The Netherlands.VBP15, a novel dissociative steroid compound, reduces NFκB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis.Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes.The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice.
P2860
Q28487685-C072D4A1-C4CB-4D9D-8A48-255B75112F36Q33736755-B0DEBA2F-979A-43A0-9542-948797BA6457Q34548198-AD77E739-D3E8-4B61-9AE9-E29B4836ED96Q34981147-2890F8EA-74FE-4ED2-8F6B-747270882EF0Q35869849-2F330B8E-E2F8-49A9-8C0C-E2C2EA1FC61CQ36223929-3AEE669A-2FD8-4883-A25C-4CF6B5C450C7Q37707600-BE7BEE7E-97D5-4D9C-BF8F-4F76C573988CQ39325703-8DAE3373-1A91-4C11-83A6-FC87F21D95EFQ44219240-4C1177BF-FEEE-41BB-BF88-80FE8D732F38Q48543939-1C391369-7F9F-483A-97AA-7D77CBC48BA4Q51720780-3DF23A06-4255-4D34-A440-397DCA233A07Q52663213-012A8F6D-F54B-4926-8285-521CA0CE1CB6Q55100454-F922457C-659A-4BF4-B75A-67C0B9F852EE
P2860
VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
@ast
VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
@en
type
label
VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
@ast
VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
@en
prefLabel
VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
@ast
VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
@en
P2093
P2860
P1476
VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
@en
P2093
Eric P Hoffman
Erica K M Reeves
Jesse M Damsker
John M McCall
P2860
P304
P356
10.1016/J.BMC.2013.02.009
P407
P577
2013-02-18T00:00:00Z